Nextech Biotechnology Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $14.9M

  • Investors
  • 7

Nextech Biotechnology General Information

Description

Manufacturer of drug delivery systems designed for pharmaceutical applications. The company offers vial reconstitution systems, ophthalmic delivery systems, vaccine delivery systems, aesthetic injection systems, pre-filled syringes, and nasal atomised devices, enabling biopharmaceutical companies to improve drug administration and packaging efficiency.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Rooms 302 and 104, Building 12, Number 619 Wangmei Road, Linping Street
  • Linping District
  • Hangzhou, Zhejiang 311100
  • China
+86 0571
Primary Industry
Medical Supplies
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Rooms 302 and 104, Building 12, Number 619 Wangmei Road, Linping Street
  • Linping District
  • Hangzhou, Zhejiang 311100
  • China
+86 0571

Nextech Biotechnology Timeline

2023202420252026
Financing Round

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Nextech Biotechnology Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Early Stage VC (Series B) 17-Sep-2026 $14.9M Completed Generating Revenue
4. Early Stage VC 22-Oct-2025 Completed Generating Revenue
3. Secondary Transaction - Private 22-Oct-2025 Completed Generating Revenue
2. Early Stage VC 05-Aug-2024 Completed Generating Revenue
1. Early Stage VC 20-Jul-2023 Completed Generating Revenue
To view Nextech Biotechnology’s complete valuation and funding history, request access »

Nextech Biotechnology Patents

Nextech Biotechnology Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20250367077-A1 Device and method for transferring liquid medicine from low-pressure sealed container to high-pressure sealed container Pending 29-May-2024
EP-4819927-A1 A convenient guiding needle Pending 06-Dec-2023
WO-2025119201-A1 A convenient guiding needle Inactive 06-Dec-2023
US-20250041520-A1 Injection device and method for using same Pending 30-May-2022
WO-2023231304-A1 Injection device, injection device without changing original structure of syringe, and method for using same Inactive 30-May-2022 A61M5/178
To view Nextech Biotechnology’s complete patent history, request access »

Nextech Biotechnology Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
Bioinsight Ventures Growth/Expansion Minority
HM Capital Venture Capital Minority
Zhejiang Zheda Qizhen Venture Capital University Minority
Chinese Academy of Sciences Holdings Government Minority
Guoke Dongfang Fund Management Growth/Expansion Minority
You’re viewing 5 of 7 investors. Get the full list »

Nextech Biotechnology FAQs

  • When was Nextech Biotechnology founded?

    Nextech Biotechnology was founded in 2021.

  • Where is Nextech Biotechnology headquartered?

    Nextech Biotechnology is headquartered in Hangzhou, China.

  • What industry is Nextech Biotechnology in?

    Nextech Biotechnology’s primary industry is Medical Supplies.

  • Is Nextech Biotechnology a private or public company?

    Nextech Biotechnology is a Private company.

  • What is Nextech Biotechnology’s current revenue?

    The current revenue for Nextech Biotechnology is .

  • How much funding has Nextech Biotechnology raised over time?

    Nextech Biotechnology has raised $14.9M.

  • Who are Nextech Biotechnology’s investors?

    Bioinsight Ventures, HM Capital, Zhejiang Zheda Qizhen Venture Capital, Chinese Academy of Sciences Holdings, and Guoke Dongfang Fund Management are 5 of 7 investors who have invested in Nextech Biotechnology.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process